{
    "Trade/Device Name(s)": [
        "Dimension\u00ae Urine Ecstasy Screen Flex\u00ae reagent cartridge",
        "EXTC Flex\u00ae reagent cartridge"
    ],
    "Submitter Information": "Dade Behring Inc.",
    "510(k) Number": "K053337",
    "Predicate Device Reference 510(k) Number(s)": [
        "K043028"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DKZ"
    ],
    "Summary Letter Date": "May 8, 2006",
    "Summary Letter Received Date": "May 9, 2006",
    "Submission Date": "Nov. 29, 2005",
    "Regulation Number(s)": [
        "21CFR862.3100"
    ],
    "Regulation Name(s)": [
        "Amphetamine test system"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Methylenedioxymethamphetamine (MDMA)",
        "closely related drugs (ecstasy)"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Dimension\u00ae clinical chemistry system"
    ],
    "Method(s)/Technology(ies)": [
        "Enzyme immunoassay (EIA)"
    ],
    "Methodologies": [
        "Enzyme immunoassay"
    ],
    "Submission Type(s)": [
        "Reagent",
        "Cartridge"
    ],
    "Document Summary": "FDA 510(k) summary for Dimension\u00ae Urine Ecstasy Screen Flex\u00ae reagent cartridge for qualitative and semi-quantitative determination of MDMA and related drugs in urine on the Dimension\u00ae clinical chemistry system",
    "Indications for Use Summary": "Qualitative and semi-quantitative determination of MDMA and closely related drugs in human urine using cutoffs of 300 or 500 ng/mL to aid in diagnosis and treatment of ecstasy use or overdose; provides preliminary results, confirmatory testing recommended",
    "fda_folder": "Toxicology"
}